Tesamorelin
Also known as · Egrifta WR · Egrifta SV · TH9507 · GHRH analog
- EvidenceApproved
- CategoryGHRH
- RoutesubQ
- Half-life~26–38 min
01 / Dosing schedule
Cited dosing
The FDA-approved dose is 1.28 mg (0.16 mL of the reconstituted 11.6 mg-per-vial solution) subcutaneously once daily. One reconstituted vial provides seven daily doses.
Egrifta WR — daily subcutaneous
| Phase | Dose & frequency |
|---|---|
| Standard dose | 1.28 mg subQ once daily |
| Vial | 11.6 mg lyophilized powder per single-patient-use vial |
| Reconstitute with | 1.3 mL of the provided bacteriostatic water |
| Draw per dose | 0.16 mL from the reconstituted vial |
| Stability | Discard unused solution 7 days after mixing |
Source · FDA label — Egrifta WR (2025) ↗
Source indication · HIV-associated lipodystrophy (Egrifta WR label).
- Injection frequency
- Once daily.
- Injection sites
- Abdomen. Rotate injection sites.
02 / Reconstitution
Reconstitution reference
Egrifta WR is 11.6 mg per vial, reconstituted with 1.3 mL of bacteriostatic water using the diluent provided. The label states the 1.28 mg dose corresponds to a 0.16 mL draw. One reconstituted vial provides seven daily doses; discard the vial 7 days after mixing.
03 / Overview
Protocol overview
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary to release endogenous growth hormone, indirectly raising IGF-1.
The only FDA-approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. This is the population all pivotal-trial data comes from.
The very short plasma half-life (~26–38 minutes) means action is transient. Daily dosing is required to maintain pulsatile GH release.
The label recommends periodic assessment of continued need, given the lack of long-term cardiovascular or diabetic-outcome data.
04 / References